Poinciana Advisors Group LLC Makes New $606,000 Investment in Bristol Myers Squibb Company $BMY

Poinciana Advisors Group LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,229 shares of the biopharmaceutical company’s stock, valued at approximately $606,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. Brighton Jones LLC increased its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its stake in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the period. United Bank increased its stake in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the period. Marshall Wace LLP purchased a new stake in Bristol Myers Squibb during the second quarter worth about $221,000. Finally, Nebula Research & Development LLC purchased a new stake in Bristol Myers Squibb during the second quarter worth about $405,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Down 2.1%

BMY stock opened at $58.19 on Wednesday. The company’s 50 day moving average price is $58.46 and its 200 day moving average price is $56.11. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market capitalization of $118.83 billion, a price-to-earnings ratio of 16.35, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the firm earned $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Analyst Ratings Changes

A number of analysts have issued reports on BMY shares. UBS Group reiterated a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Guggenheim reiterated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Cantor Fitzgerald upped their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 8th. Finally, Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $61.31.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.